The company has completed a successful European First in Human study, the TANDEM I study, demonstrating sustained reductions in tricuspid regurgitation and marked improvements in patients’ quality of life metrics.
Company Description
CroíValve is a clinical stage medical device company focused on the development of a novel transcatheter device for the treatment of tricuspid regurgitation. The DUO™ System is designed to restore valve function while leaving the patient’s right heart and native valve apparatus untouched through an innovative anchoring mechanism.
Market
Cardiology
Location
Ireland
Coinvestors
MedTech & Irrus Syndicates, Ascentifi, Furthr, Broadview Ventures, Atlantic Bridge University Fund, Enterprise Ireland, Elkstone, SOSV, IAG Capital Partners